Clinical trial failures

Sponsor hub

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University clinical trial failures

Review 31 stopped clinical trials from Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 0 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials31
Likely biological signals0
Shown below31

Dominant stop reasons

OPERATIONAL
23
OTHER/UNKNOWN
8

Notable sponsors

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
31

Related phases

Phase II
13
Phase I
11
Unknown
6
Early Phase I
1

Crawlable stopped-trial records

Open Explore

Showing up to 31 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT02555189: Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression

Phase I Castration-Resistant Prostate Carcinoma trial by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. Stop reason: OPERATIONAL.

Sponsor-PI decision. An analysis of the primary endpoint concluded that the addition of ribociclib to standard of care enzalutamide did not demonstrate benefit, an all active subjects were removed from the study.